Annals of medicine and surgery (2012)|2026|Tayyaba S, Ali U, Osman Abufatima I
PMID: 41675811
15038 studies
INTRODUCTION: Smoking remains a significant global health concern, associated with numerous preventable diseases and high mortality rates. Glucagon-like peptide-1 receptor agonists (GLP-1), known for its roles in glucose regulation and appetite contr…
BACKGROUND: Periodontal ligament stem cells (PDLSCs) hold great promise for periodontal regeneration therapy. However, their self-renewal and multilineage differentiation capabilities are often compromised by adverse factors in the periodontal microe…
Semaglutide (SEM) is a glucagon-like peptide-1 (GLP-1) receptor agonist formulated for oral delivery with the absorption enhancer salcaprozate sodium (SNAC). Although oral SEM achieves 0.4-1% bioavailability through gastric epithelial uptake, gastroi…
AIMS: Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic disease. Its role in the immediate postacute coronary syndrome (AC…
BACKGROUND: People with schizophrenia experience markedly reduced health-related quality of life (QoL), partly driven by obesity and metabolic dysregulation. Glucagon-like peptide-1 receptor agonists such as semaglutide induce substantial weight loss…
Peptide hormone-based weight-loss therapeutics have gained increasing attention, driven amongst other reasons, by the clinical and commercial success of semaglutide. Their increasing accessibility raises concerns about their potential misuse in sport…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging as a cornerstone in the management of type 2 diabetes and obesity. The perioperative implications of GLP-1RAs in orthopaedic surgery are a growing area of interest; however, their effe…
The incretin hormone glucagon-like peptide-1 (GLP-1) exerts potent effects on glucose metabolism, prompting the development of therapeutic strategies that enhance activity of the GLP-1 receptor (GLP-1R) pathway. Inhibitors of dipeptidyl peptidase 4 (…
BACKGROUND: Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for sever…
BACKGROUND: Diabetic nephropathy (DN) is a major microvascular complication of type 2 diabetes and a leading cause of end-stage renal disease. Both canagliflozin and semaglutide are recommended for diabetic nephropathy, yet direct evidence comparing…
Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-ye…
Pediatric obesity is a common chronic disease with serious long-term health consequences. This narrative review compares current international and national recommendations for the diagnosis and management of pediatric obesity. We focus on guidance fr…
Spinal epidural lipomatosis (SEL) is a rare cause of lumbar canal stenosis, typically linked to obesity or corticosteroid use. Severe cases often require decompression. We report a 48-year-old man with chronic low back pain and morbid obesity (153 kg…
TOPIC: This systematic review and meta-analysis evaluates whether semaglutide use, compared with non-glucagon-like peptide-1 receptor agonist (GLP-1 RA) receptor agonist therapies, is associated with nonarteritic anterior ischemic optic neuropathy (N…
INTRODUCTION: Dual GIP/GLP-1 receptor agonists have gained significant attention in clinical applications because of their remarkable efficacy in reducing obesity and type 2 diabetes. However, the mechanisms by which these dual agonists affect system…
The approval of resmetirom and semaglutide for fibrotic MASH has created an urgent need for tools that will aid identify candidates for drug therapy and assess response non-invasively. Existing NITs often misclassify patients with fibrotic MASH. Nove…
BACKGROUND: With the shortage of innovator semaglutide or tirzepatide products resolved, compounding pharmacies can only legally sell unique products. Unique products could have a different route of administration or dosing, or could include addition…
Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential r…